Impax spending $52M to expand Taiwan plant

Pushed to the limit at its manufacturing plants and eyeing production of a Parkinson’s disease drug for GlaxoSmithKline, Impax Laboratories Inc. is undertaking a $52 million expansion of its year-old Taiwan facility.
Hayward-based Impax (NASDAQ: IPXL) said it would expand the 100,000-square-foot plant in Chunan, Taiwan, so it could produce up to 700 million tablets or capsules a year. An Impax spokesman did not say how large the expansion would be, but he said the plant currently can make as many as 450 million drugs a year.
The expansion, the first phase of a plan to increase the plant’s capacity to 1.5 billion tablets or capsules a year, should be completed by the end of 2012.